Trial Profile
Open-label Single Arm Phase II Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Brain metastases; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 21 Jun 2016 Status changed from not yet recruiting to recruiting.
- 31 May 2016 New trial record